CBD: A compound found in the cannabis plant has health benefits and does not have abuse potential.
The World Health Organization (WHO) Expert Committee on Drug Dependence focused on cannabidiol, or CBD, one of the naturally occurring cannabinoids found in cannabis plants. After reviewing evidence from animal and human studies, the WHO has declared that CBD – the relaxant property of cannabis used in medical marijuana – should not be a scheduled drug.
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”
What Is Medical Marijuana?
via Harvard Health
Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.The experts said that CBD might be able to treat epilepsy, although results are mixed. Other conditions it might treat are Alzheimer’s disease, Parkinson’s, anxiety, and depression. In addition, CBD may ease inflammation, provide antioxidants, and relieve pain.
But after months of deliberation and investigation, WHO has concluded that cannabidiol (CBD) is a useful treatment for epilepsy and palliative care, and does not carry any addiction risks. Furthermore, CBD should not be a Schedule 1 substance.Twenty-nine states and Washington, D.C., have legalized the use of marijuana for recreational or medicinal purposes, but it still remains a federal crime. However, despite regulation, CBD is a popular and often sold product. CBD is usually taken as a capsule, tincture form, CBD isolate, or as a nasal spray. CBD does not produce the high you get from THC. In fact, CBD appears to have effects opposite of THC. As a result, the WHO announcement drew a positive response from marijuana advocates. And consequently, criticism from those who don’t want it to be legal.
The World Health Organization VS. The DEA
via Merry Jane
The conclusion of the WHO flies in the face of the view of the U.S. Drug Enforcement Administration (DEA). The DEA stated CBD must be treated the same as THC and other cannabinoids from a cannabis plant, and it should remain a Schedule I drug.
NORML Canada Response
Marijuana advocates applauded the WHO’s conclusion. “It was terrific to see WHO acknowledge what other scientific research has already stated,” says Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML).
Scott Chipman, Southern California chairman of Citizens Against Legalizing Marijuana (CALM), took issue with the report.
“We need to maintain a strictly scientific perspective and protocols when it comes to new drugs,” he says. “We need double-blind studies related to marijuana and all components. research on the harms versus the benefits, identification of the side effects and specific ailments identified through these studies. even for CBD,” he says.
However, he did say some ongoing drug studies of CBD do show promise in treating seizure disorders. On the other hand, he also sees potential problems with the drugs. There have been many concerns about contamination and other potential harms.